The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line

Anticancer Research

Volumn 33, Issue 5, 2013, Pages 1845-1851

  Josset, Elodie ^a   Burckel, Hél̀ene ^a   Noël, Georges ^a   Bischoff, Pierre ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

radiation; Autophagy; Glioblastoma; RAD001; Temozolomide

Indexed keywords

EVEROLIMUS; TEMOZOLOMIDE;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CHEMORADIOTHERAPY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; GAMMA IRRADIATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; TUMOR GROWTH;

Γ-RADIATION; AUTOPHAGY; GLIOBLASTOMA; RAD001; TEMOZOLOMIDE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AUTOPHAGY; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL PROLIFERATION; CESIUM RADIOISOTOPES; DACARBAZINE; DRUG SYNERGISM; FLOW CYTOMETRY; GAMMA RAYS; GLIOBLASTOMA; HUMANS; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 84878186041     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Johnson DR and Chang SM: Recent medical management of glioblastoma. Adv Exp Med Biol 746: 26-40, 2012.
2. Pommier P, Hu Y, Baron MH, Chapet O and Balosso J: Particle therapy: Carbon ions. Bull Cancer 97: 819-829, 2010.
3. Weller M: Novel diagnostic and therapeutic approaches to malignant glioma. Swiss Med Wkly 141: 13210, 2011.
4. Dancey J: mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 7: 209-219, 2010.
5. Dumont FJ and Bischoff P: Disrupting the mTOR signaling network as a potential strategy for the enhancement of cancer radiotherapy. Curr Cancer Drug Target 12: 899-924, 2012.
6. Lee JJ, Kim BC, Park MJ, Lee YS, Kim YN, Lee BL and Lee JS: PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiation. Cell Death Differ 4: 666-677, 2011.
7. Annovazzi L, Mellai M, Caldera V, Valente G, Tessitore L and Schiffer D: mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma. Anticancer Res 29: 3087-3094, 2009.
8. Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA, Polley MY, Ozawa T, Berger MS, Aftab DT, Prados MD and Haas-Kogan DA: Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol 13: 384-392, 2011.
9. Lefranc F and Kiss R: Autophagy, the Trojan horse to combat glioblastomas. Neurosurg Focus 20: E7, 2006.
10. Emdad L, Qadeer ZA, Bederson LB, Kothari HP, Uzzaman M and Germano IM: Is there a common upstream link for autophagic and apoptotic cell death in human high-grade gliomas? Neuro Oncol 13: 725-735, 2011.
11. Riccardi C and Nicoletti I: Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 1: 1458-1461, 2006.
12. Schleicher SM, Moretti L, Varki V and Lu B: Progress in the unraveling of the endoplasmic reticulum stress/autophagy pathway and cancer: Implications in future therapeutic approaches. Drug Resist Updat 13: 76-86, 2010.
13. Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W, DiPaola RS, Lotze MT and White E: Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 15: 654-666, 2011.
14. Dalby KN, Tekedereli I, Lopez-Berestein G and Ozpolat B: Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 6: 322-329, 2010.
15. White EJ, Martin V, Liu JL, Klein SR, Piya S, Gomez-Manzano C, Fueyo J and Jiang H: Autophagy regulation in cancer development and therapy. Am J Cancer Res 1: 362-372, 2011.
16. Bischoff P, Josset E and Dumont FJ: Novel pharmacological modulators of autophagy and therapeutic prospects. Expert Opin Ther Pat 22: 1053-1079, 2012.
17. Lomonaco SL, Finniss S, Xiang C, Lee HK, Jiang W, Lemke N, Rempel SA, Mikkelsen T and Brodie C: Cilengitide induces autophagy-mediated cell death in glioma cells. Neuro Oncol 13: 857-865, 2011.
18. Natsumeda M, Aoki H, Miyahara H, Yajima N, Uzuka T, Toyoshima Y, Kakita A, Takahashi H and Fujii Y: Induction of autophagy in temozolomide treated malignant gliomas. Neuropathology 31: 486-493, 2011.
19. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y and Kondo S: Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 11: 448-457, 2004. (Pubitemid 38489422)
20. Carmo A, Carvalheiro H, Crespo I, Nunes I and Lopes MC: Effect of temozolomide on the U-118 glioma cell line. Oncol Lett 2: 1165-1170, 2011.
21. Palumbo S, Pirtoli L, Tini P, Cevenini G, Calderaro F, Toscano M, Miracco C and Comincini S: Different involvement of autophagy in human malignant glioma lines undergoing irradiation and temozolomide combined treatments. J Cell Biochem 113: 2308-2318, 2012.
22. Voss V, Senft C, Lang V, Ronellenfitsch MW, Steinbach JP, Seifert V and Kögel D: The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma. Mol Cancer Res 8: 1002-1016, 2010.
23. Milano V, Piao Y, LaFortune T and de Groot J: Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. Mol Cancer Ther 8: 394-406, 2009.
24. Kuwahara Y, Oikawa T, Ochiai Y, Roudkenar MH, Fukumoto M, Shimura T, Ohtake Y, Ohkubo Y, Mori S, Uchiyama Y and Fukumoto M: Enhancement of autophagy is a potential modality for tumors refractory to radiotherapy. Cell Death Differ 11: 448-457, 2011.
25. Zois CE and Koukourakis MI: Radiation-induced autophagy in normal and cancer cells: Towards novel cytoprotection and radiosensitization policies? Autophagy 5: 442-450, 2009.
26. Zhuang W, Li B, Long L, Chen L, Huang Q and Liang Z: Induction of autophagy promotes differentiation of glioma-initiating cells and their radiosensitivity. Int J Cancer 129: 2720-2731, 2011.
27. Albert JM, Kim KW, Cao C and Lu B: Targeting the Akt/mammalian target of rapamycin for radiosenzitization of breast cancer. Mol Cancer Ther 5: 1183-1189, 2006. (Pubitemid 43881310)
28. Altmeyer A, Josset E, Denis JM, Gueulette J, Slabbert J, Mutter D, Noël G and Bischoff P: The mTOR inhibitor RAD001 augments radiation-induced growth inhibition in a hepatocellular carcinoma cell line by increasing autophagy. Int J Oncol 41: 1381-1386, 2012.
29. Mason WP, MacNeil M, Kavan P, Easaw J, Macdonald D, Thiessen B, Urva S, Lwin Z, McIntosh L and Eisenhauer E: A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: An NCIC CTG study. Invest New Drugs 30: 2344-51, 2012.
30. Sarkaria JN, Galanis E, Wu W, Peller PJ, Giannini C, Brown PD, Uhm JH, McGraw S, Jaeckle KA and Buckner JC: North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 81: 468-475, 2011.
31. Hainsworth JD, Shih KC, Shepard GC, Tillinghast GW, Brinker BT and Spigel DR: Phase II study of concurrent radiation therapy, temozolomide, and bevacizumad followed by bevacizumad/ everolimus as first-line treatment for patients with glioblastoma. Clin Adv Hematol Oncol 10: 240-246, 2012.